Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]

Insulet (Nasdaq:PODD) announced data supporting the use of its Omnipod 5 automated insulin delivery system in young children.

Acton, Massachusetts-based Insulet’s Omnipod 5, which became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. earlier this year, significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use.

Get the full story at our sister site, Drug Delivery Business News.